BRPI0905660A2 - "método para reduzir ou inibir a angiogênese" - Google Patents

"método para reduzir ou inibir a angiogênese"

Info

Publication number
BRPI0905660A2
BRPI0905660A2 BRPI0905660-2A BRPI0905660A BRPI0905660A2 BR PI0905660 A2 BRPI0905660 A2 BR PI0905660A2 BR PI0905660 A BRPI0905660 A BR PI0905660A BR PI0905660 A2 BRPI0905660 A2 BR PI0905660A2
Authority
BR
Brazil
Prior art keywords
reduce
inhibit angiogenesis
angiogenesis
inhibit
Prior art date
Application number
BRPI0905660-2A
Other languages
English (en)
Inventor
Weilan Ye
Han Lu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0905660A2 publication Critical patent/BRPI0905660A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
BRPI0905660-2A 2008-01-14 2009-01-14 "método para reduzir ou inibir a angiogênese" BRPI0905660A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2096008P 2008-01-14 2008-01-14
PCT/US2009/030969 WO2009091810A1 (en) 2008-01-14 2009-01-14 Methods for inhibiting angiogenesis using egfl8 antagonists

Publications (1)

Publication Number Publication Date
BRPI0905660A2 true BRPI0905660A2 (pt) 2015-07-07

Family

ID=40350246

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0905660-2A BRPI0905660A2 (pt) 2008-01-14 2009-01-14 "método para reduzir ou inibir a angiogênese"

Country Status (14)

Country Link
US (1) US9549971B2 (pt)
EP (1) EP2235189A1 (pt)
JP (2) JP2011510011A (pt)
KR (1) KR20100102152A (pt)
CN (1) CN101970670B (pt)
AU (1) AU2009205428B2 (pt)
BR (1) BRPI0905660A2 (pt)
CA (1) CA2710619A1 (pt)
HK (1) HK1149205A1 (pt)
IL (1) IL206730A0 (pt)
MX (1) MX2010007669A (pt)
RU (1) RU2486200C2 (pt)
WO (1) WO2009091810A1 (pt)
ZA (1) ZA201005341B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025367B1 (ru) * 2009-08-17 2016-12-30 Тракон Фармасьютикалз, Инк. Комбинированная терапия рака с помощью антител против эндоглина и агентов против vegf
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US9789213B2 (en) * 2012-03-27 2017-10-17 London Health Sciences Centre Research Inc. EGFL7 targeting and/or binding polypeptides and methods for inhibiting angiogenesis
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
KR101504813B1 (ko) * 2012-10-23 2015-03-23 부산대학교 산학협력단 Egfl8의 작용물질 또는 길항물질을 포함하는 면역조절용 약학 조성물
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
CN112213495B (zh) * 2020-09-18 2022-10-28 广州中医药大学第三附属医院(广州中医药大学第三临床医学院、广州中医药大学附属骨伤科医院、广州中医药大学骨伤科研究所) 一种辅助诊断或诊断股骨头坏死的标志物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US20030180784A1 (en) * 1997-04-04 2003-09-25 Millennium Pharmaceuticals, Inc. Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
US20030166907A1 (en) * 1997-06-18 2003-09-04 Zymogenetics, Inc. Mammalian neuro-growth factor like protein
WO2001012210A1 (en) 1999-08-13 2001-02-22 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras
AU2003257111A1 (en) 2002-08-02 2004-02-23 Incyte Corporation Extracellular messengers
WO2005117968A2 (en) * 2004-04-14 2005-12-15 Genentech, Inc. Compositions and methods comprising an egfl7 antagonist for modulating vascular development
ZA200704338B (en) 2004-10-29 2009-03-25 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
JP5244103B2 (ja) * 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法

Also Published As

Publication number Publication date
CN101970670A (zh) 2011-02-09
MX2010007669A (es) 2010-08-04
HK1149205A1 (en) 2011-09-30
CN101970670B (zh) 2013-08-21
AU2009205428B2 (en) 2014-10-30
KR20100102152A (ko) 2010-09-20
EP2235189A1 (en) 2010-10-06
US20110014194A1 (en) 2011-01-20
CA2710619A1 (en) 2009-07-23
ZA201005341B (en) 2014-12-23
IL206730A0 (en) 2010-12-30
US9549971B2 (en) 2017-01-24
RU2010133957A (ru) 2012-02-27
JP2011510011A (ja) 2011-03-31
WO2009091810A1 (en) 2009-07-23
AU2009205428A1 (en) 2009-07-23
JP2014221769A (ja) 2014-11-27
RU2486200C2 (ru) 2013-06-27

Similar Documents

Publication Publication Date Title
BRPI1006415A2 (pt) "método para controlar fungos nocivos"
BRPI0810929A2 (pt) "método para proteger"
BRPI0906082A2 (pt) "sanitizador hidratante para as mãos"
BRPI0812603A2 (pt) "método para prevenir a redução de pontes dissulfeto"
BRPI0922904A2 (pt) "compostos"
BRPI0812631A2 (pt) para tratar um líquido"
BR112012004593A2 (pt) "método"
DK2299862T3 (da) Sål til en sko, i særdeleshed til en løbesko
CU24162B1 (es) Derivados 5-aril-1,2,4-triazolona ligada a bisarilo sustituidos
CR20140154A (es) Compuestos para inhibir la progresión mitotica
BRPI1015540A2 (pt) ''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750''
BRPI0905660A2 (pt) "método para reduzir ou inibir a angiogênese"
BRPI0821003A2 (pt) Método para aumentar a imunorreatividade
BRPI1011051A2 (pt) "desinfetante para as mãos"
BRPI0914533A2 (pt) "métodos"
BRPI0922805A2 (pt) método para prevenir ou reduzir a carcinogênese ou o estresse oxidativo
BRPI1015102A2 (pt) Método para induzir formação de etanol.
BRPI0916171A2 (pt) "método para produzir uma característica de alívio de cintura"
BRPI1010178A2 (pt) "válvula"
BRPI0921679A2 (pt) composto útil para tratar celulite
BRPI1010778A2 (pt) "escada dupla"
BRPI1009768A2 (pt) "método para acentuar o sinal antes da broca"
MA30860B1 (fr) Myrtillier denomme "c97-390"
BRPI0821269A2 (pt) Métodos para inibir a formação de cicatrizes
BRPI1013017A2 (pt) "17beta-alquil-17alfa-óxi-estratrienos"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2549 DE 12-11-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.